CY1110447T1 - Νιτροξυ-παραγωγα της λοσαρτανης, της βαλσατρανης, της κανδερτανης, της τελμισατρανης, της επροσαρτανης και της ολμεσαρτανης ως αποκλειστικες του υποδοχεα της αγγειοτασινης-ii για την αγωγη καρδιαγγειακων παθησεων - Google Patents

Νιτροξυ-παραγωγα της λοσαρτανης, της βαλσατρανης, της κανδερτανης, της τελμισατρανης, της επροσαρτανης και της ολμεσαρτανης ως αποκλειστικες του υποδοχεα της αγγειοτασινης-ii για την αγωγη καρδιαγγειακων παθησεων

Info

Publication number
CY1110447T1
CY1110447T1 CY20081100385T CY081100385T CY1110447T1 CY 1110447 T1 CY1110447 T1 CY 1110447T1 CY 20081100385 T CY20081100385 T CY 20081100385T CY 081100385 T CY081100385 T CY 081100385T CY 1110447 T1 CY1110447 T1 CY 1110447T1
Authority
CY
Cyprus
Prior art keywords
losartan
nitroxy
valsatran
telmisatran
olmesartani
Prior art date
Application number
CY20081100385T
Other languages
English (en)
Inventor
Nicoletta Almirante
Soldato Piero Del
Ennio Ongini
Original Assignee
Nicox S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nicox S.A. filed Critical Nicox S.A.
Publication of CY1110447T1 publication Critical patent/CY1110447T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/20—Two benzimidazolyl-2 radicals linked together directly or via a hydrocarbon or substituted hydrocarbon radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Νιτροξυ-παράγωγα των αποκλειστών υποδοχέα αγγειοτασίνης-ΙΙ λοσαρτάνη, βαλσαρτάνη, κανδεσαρτάνη, τελμισαρτάνη, εμπροσαρτάνη, και ολμεσαρτάνη και παρόμοιες ενώσεις τύπου (Ι): R-(Y-ONO2)s όπου το R είναι τύπου (ΙΙ) ή (ΙΙΙ): το R0 είναι π.χ.: και το R1 είναι: (ΙΙa), (IIb), (IIc), (IId) ή (IIe).
CY20081100385T 2003-07-31 2008-04-07 Νιτροξυ-παραγωγα της λοσαρτανης, της βαλσατρανης, της κανδερτανης, της τελμισατρανης, της επροσαρτανης και της ολμεσαρτανης ως αποκλειστικες του υποδοχεα της αγγειοτασινης-ii για την αγωγη καρδιαγγειακων παθησεων CY1110447T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03102379 2003-07-31
EP04766269A EP1653950B1 (en) 2003-07-31 2004-07-20 Nitrooxy derivatives of losartan, valsatan, candesartan, telmisartan, eprosartan and olmesartan as angiotensin-ii receptor blockers for the treatment of cardiovascular diseases

Publications (1)

Publication Number Publication Date
CY1110447T1 true CY1110447T1 (el) 2015-04-29

Family

ID=34112476

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081100385T CY1110447T1 (el) 2003-07-31 2008-04-07 Νιτροξυ-παραγωγα της λοσαρτανης, της βαλσατρανης, της κανδερτανης, της τελμισατρανης, της επροσαρτανης και της ολμεσαρτανης ως αποκλειστικες του υποδοχεα της αγγειοτασινης-ii για την αγωγη καρδιαγγειακων παθησεων

Country Status (30)

Country Link
US (1) US20060276523A1 (el)
EP (1) EP1653950B1 (el)
JP (1) JP2007500684A (el)
KR (1) KR20060056352A (el)
CN (1) CN100496490C (el)
AR (1) AR045145A1 (el)
AT (1) ATE383155T1 (el)
AU (1) AU2004260830B2 (el)
BR (1) BRPI0413028A (el)
CA (1) CA2534451A1 (el)
CY (1) CY1110447T1 (el)
DE (1) DE602004011230T2 (el)
DK (1) DK1653950T3 (el)
EC (1) ECSP066334A (el)
ES (1) ES2299861T3 (el)
HK (1) HK1095093A1 (el)
HR (1) HRP20060084A2 (el)
IL (1) IL172703A0 (el)
IS (1) IS2534B (el)
MA (1) MA27987A1 (el)
MX (1) MXPA06001263A (el)
NO (1) NO20060900L (el)
NZ (1) NZ544463A (el)
PL (2) PL379420A1 (el)
PT (1) PT1653950E (el)
RU (1) RU2374240C2 (el)
SI (1) SI1653950T1 (el)
UA (1) UA87983C2 (el)
WO (1) WO2005011646A2 (el)
ZA (1) ZA200600856B (el)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1984871A (zh) 2004-07-20 2007-06-20 尼科克斯公司 制备硝基氧基酯、硝基氧基硫酯、硝基氧基碳酸酯和硝基氧基硫代碳酸酯的方法、用于所述方法的中间体及其制备
WO2006079610A1 (en) * 2005-01-31 2006-08-03 Nicox S.A. Nitrooxy sartan derivatives as angiotensin ii receptor blockers for the treatment of cardiovascular and inflammatory diseases
CN101024643A (zh) 2006-02-20 2007-08-29 上海艾力斯医药科技有限公司 咪唑－5－羧酸类衍生物、制备方法及其应用
TW200821303A (en) * 2006-08-08 2008-05-16 Speedel Experimenta Ag Organic compounds
WO2008058402A1 (en) 2006-11-17 2008-05-22 Queen's University At Kingston Compounds and methods for treating protein folding disorders
WO2008067687A1 (fr) * 2006-12-06 2008-06-12 Shanghai Allist Pharmaceutical., Inc. Sels de dérivés d'acide imidazol-5-carboxylique, procédés de préparation et utilisation
TW200831079A (en) * 2006-12-13 2008-08-01 Merck & Co Inc Angiotensin II receptor antagonists
JP2010513273A (ja) * 2006-12-13 2010-04-30 メルク アンド カンパニー インク． アンジオテンシンｉｉ受容体拮抗薬
CN101214242A (zh) * 2007-01-05 2008-07-09 上海艾力斯医药科技有限公司 新的药用组合物
EP1980559A1 (en) * 2007-04-10 2008-10-15 CTG Pharma S.r.l. Cardiovascular agents
CN101317842A (zh) 2007-06-07 2008-12-10 上海艾力斯医药科技有限公司 一种咪唑-5-羧酸衍生物的治疗用途
CN101407511B (zh) * 2007-10-11 2013-01-09 上海艾力斯生物医药有限公司 一种结晶型的咪唑-5-羧酸衍生物
AR069340A1 (es) * 2007-11-26 2010-01-13 Merck & Co Inc Antagonistas del receptor de angiotensina ii
PT2230934E (pt) 2007-12-14 2012-11-20 Aerodesigns Inc Distribuir produtos alimentares aerossolizáveis
JP2011510082A (ja) * 2008-01-24 2011-03-31 メルク・シャープ・エンド・ドーム・コーポレイション アンジオテンシンｉｉ受容体拮抗薬
WO2009099853A2 (en) 2008-02-08 2009-08-13 Merck & Co., Inc. Angiotensin ii receptor antagonists
EP2250164A2 (en) * 2008-02-26 2010-11-17 Nicox S.A. Angiotensin ii receptor blocker derivatives
WO2009106470A2 (en) * 2008-02-26 2009-09-03 Nicox S.A. Angiotensin ii receptor antagonists
WO2009140111A1 (en) * 2008-05-15 2009-11-19 Merck & Co., Inc. Angiotensin ii receptor antagonists
CN101596189A (zh) * 2008-06-05 2009-12-09 上海艾力斯生物医药有限公司 含有咪唑-5-羧酸类衍生物的药用组合物
WO2009150007A1 (en) * 2008-06-09 2009-12-17 Nicox S.A. Angiotensin ii receptor antagonists
AR073259A1 (es) * 2008-07-29 2010-10-28 Merck & Co Inc Derivados de furosemida utiles como diureticos
WO2010015447A1 (en) * 2008-08-08 2010-02-11 Nicox S.A. Angiotensin ii receptor antagonists
EP2194048A1 (en) 2008-12-02 2010-06-09 Dirk Sartor Nitrate esters for the treatment of vascular and metabolic diseases
JP2012511002A (ja) 2008-12-05 2012-05-17 メルク・シャープ・エンド・ドーム・コーポレイション アンジオテンシンｉｉ受容体アンタゴニストとしてのニトロオキシ誘導体
EA020103B1 (ru) 2009-01-23 2014-08-29 Ханми Сайенс Ко., Лтд. Твердая фармацевтическая композиция, содержащая амлодипин и лозартан, и способ ее получения
CA2796710A1 (en) 2010-04-19 2011-10-27 Cardiolynx Ag Valsartan derivatives carrying nitrogen oxide donors for the treatment of vascular and metabolic diseases
AU2011243947A1 (en) * 2010-04-23 2012-12-06 Piramal Enterprises Limited Nitric oxide releasing prodrugs of therapeutic agents
WO2011160974A2 (en) 2010-06-21 2011-12-29 Nicox S.A. Statin derivatives
JO3350B1 (ar) 2011-03-07 2019-03-13 Merck Sharp & Dohme مشتقات حلقية غير متجانسة محتوية على مجموعات أمينو أولية ومركبات داي أزينيومديولات
CA2897571C (en) 2013-01-21 2018-12-18 Apparao Satyam Nitric oxide releasing prodrugs of therapeutic agents containing at least one carboxylic acid group
CN103275074B (zh) * 2013-06-21 2016-08-10 黄冈鲁班药业股份有限公司 一种奥美沙坦衍生物及其制备方法
CN105820125B (zh) * 2015-01-09 2018-12-07 北京中医药大学 一种用于治疗高血压的化合物及其制备方法和用途
CN108349911B (zh) 2015-09-07 2022-05-13 浙江华海药业股份有限公司 可释放一氧化氮的前药分子
CN106800537B (zh) * 2017-01-18 2019-02-01 广东隆赋药业股份有限公司 丁苯酞-替米沙坦杂合物及其制备方法和用途
CN108892624B (zh) * 2018-06-20 2020-12-15 重庆威鹏药业有限公司 沙库巴曲硝基氧衍生物及其制备方法和应用
CN114105881B (zh) * 2020-08-31 2024-01-26 沈阳海诺威医药科技有限公司 血小板聚集抑制剂及其制备方法和用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0955294B1 (en) * 1989-06-14 2003-09-24 Smithkline Beecham Corporation Imidazolyl-alkenoic acid
IT1311924B1 (it) * 1999-04-13 2002-03-20 Nicox Sa Composti farmaceutici.
CA2420055C (en) * 2000-08-25 2010-06-01 Takeda Chemical Industries, Ltd. Fibrinogen-lowering agent
ITMI20011744A1 (it) * 2001-08-09 2003-02-09 Nicox Sa Farmaci per le vasculopatie

Also Published As

Publication number Publication date
IL172703A0 (en) 2006-04-10
AU2004260830B2 (en) 2010-04-29
IS8332A (is) 2006-02-27
CN100496490C (zh) 2009-06-10
CA2534451A1 (en) 2005-02-10
RU2006105804A (ru) 2007-09-20
ATE383155T1 (de) 2008-01-15
DK1653950T3 (da) 2008-05-26
MA27987A1 (fr) 2006-07-03
AU2004260830A1 (en) 2005-02-10
AR045145A1 (es) 2005-10-19
HRP20060084A2 (hr) 2006-04-30
PL1653950T3 (pl) 2008-08-29
WO2005011646A3 (en) 2005-04-21
MXPA06001263A (es) 2006-04-11
ES2299861T3 (es) 2008-06-01
US20060276523A1 (en) 2006-12-07
RU2374240C2 (ru) 2009-11-27
PL379420A1 (pl) 2006-09-04
HK1095093A1 (en) 2007-04-27
NZ544463A (en) 2009-10-30
CN1832742A (zh) 2006-09-13
DE602004011230T2 (de) 2009-01-02
IS2534B (is) 2009-08-15
PT1653950E (pt) 2008-04-11
ZA200600856B (en) 2007-05-30
BRPI0413028A (pt) 2006-10-03
ECSP066334A (es) 2006-07-28
JP2007500684A (ja) 2007-01-18
NO20060900L (no) 2006-02-24
WO2005011646A2 (en) 2005-02-10
UA87983C2 (ru) 2009-09-10
SI1653950T1 (sl) 2008-06-30
EP1653950A2 (en) 2006-05-10
KR20060056352A (ko) 2006-05-24
EP1653950B1 (en) 2008-01-09
DE602004011230D1 (de) 2008-02-21

Similar Documents

Publication Publication Date Title
CY1110447T1 (el) Νιτροξυ-παραγωγα της λοσαρτανης, της βαλσατρανης, της κανδερτανης, της τελμισατρανης, της επροσαρτανης και της ολμεσαρτανης ως αποκλειστικες του υποδοχεα της αγγειοτασινης-ii για την αγωγη καρδιαγγειακων παθησεων
CY1123705T1 (el) Αλατα και πολυμορφα μιας ενωσης τετρακυκλινης
CY1109610T1 (el) Παραγωγο βενζιμιδαζολης και η χρηση αυτου ως ανταγωνιστου του υποδοχεα αιι
CY1112474T1 (el) Πιπεριδινικοι gpcr αγωνιστες
CY1114287T1 (el) Νεα πυραζολο-4-ν-αλκοξυκαρβοξαμιδια ως μικροβιοκτονα
BRPI0605921A2 (pt) compostos orgánicos
EA200801128A1 (ru) Пери-конденсированные трициклические соединения, полезные в качестве антибактериальных средств
EA200801428A1 (ru) Производные пиридиазинона для лечения опухолей
CY1112886T1 (el) Ανοσοκατασταλτικος παραγοντας ο οποιος περιλαμβανει μια ετεροκυκλικη ενωση ως δραστικο συστατικο
ECSP10010722A (es) Compuestos orgánicos
ECSP088367A (es) Derivados de bifenilo y su uso en el tratamiento de la hepatitis c
CY1113907T1 (el) Δικυκλικες ετεροαρυλ ενωσεις
CR8451A (es) Uso de derivados de n-arilhidracina para combatir pestes
ECSP099225A (es) Compuestos antagonistas del receptor de glucagón, composiciones que contienen dichos compuestos y procedimientos de uso
ATE482932T1 (de) N-alkynyl-2-(substituierte aryloxy)alkylthioamide derivate als fungizide
CL2012002526A1 (es) Uso de compuestos inhibidores de dpp iv de formula (i) o (ii) o una de sus sales, para el tratamiento de falla cardiaca.
ME01992B (me) Jedinjenje diarilhidantoina
CY1113352T1 (el) Ενωση σπειρο-δακτυλιου και χρηση αυτης για ιατρικους σκοπους
BRPI0510177B8 (pt) composto, composição farmacêutica e uso do mesmo
ECSP10010334A (es) Derivados de quinolina y su uso como fungicidas
ATE377419T1 (de) Substituierte 4-alkoxyoxazol derivate als ppar agonisten
TN2010000045A1 (en) Novel herbicides
ECSP099442A (es) Derivados de heteroaril-pirrolidinil- y -piperidinil-cetona
EA200801366A1 (ru) Производные 3,6-дигидро-2-оксо-6н-1,3,4-тиадиазина
CY1111432T1 (el) Τετραϋδροκινολινες για χρηση ως διαμορφωτες της μιτοτικης κινητικης πρωτεϊνης eg5